Metyrapone Treatment in Mild Autonomous Cortisol Secretion: Cardiovascular Benefits and Mechanistic Insights
A 12-week metyrapone regimen lowers blood pressure and reduces epicardial fat in patients with mild autonomous cortisol secretion, suggesting cardiovascular improvements without altering cardiac morphology or function.